NPIL, Merck in research deal for cancer drugs
NPIL, Merck in research deal for cancer drugs

Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.

whatsapp--v1